Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | CuttingEdgeInfo Reports | Neurodegenerative Market Forecast to 2013 (TA222)

Neurodegenerative Market Forecast to 2013 (TA222)

Comprehensive Forecasts for Neurodegenerative Conditions

The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:

* Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012.

* The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.

Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients’ quality of life could see hundreds of millions — or even billions — of dollars in sales.

In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimer’s, Multiple Sclerosis and Parkinson’s markets.

Detailed Product Profiles

CEI’s veteran analysts examine 40 brands representing different classes and stages of development. The profiled products represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:

* Drug history

* Competitive and strategic positioning:

o Current status of drug

o Sales position within its class

o Presence or strength of competition

* Market growth opportunities:

o Analysis combines new/current sales or clinical trial info with projections, predictions, insights

o Analysis supported by sales projection charts, covering up to the next 7 years

o Materiality charts, for 2007 and 2012

* Charts containing market exclusivity and patent information for approved drugs

* Clinical trial data tables to quickly show clinical detail:

o Describes trial and why drug is in its current stage

o Progress of drug

Analyses weigh the challenges and opportunities of each indication, class, and individual brand. Which brands will reap dividends and why? Whose sales are expected to drop? Which experimental therapies represent the next great medical breakthrough? Who will be the markets’ leaders in the next decade?

Give your brand team all the data it needs to make critical product decisions!

More than 40 products from 25+ companies, including:

Eli Lilly

Pfizer

Wyeth

Bristol-Myers Squibb

Biogen Idec Genentech

GlaxoSmithKline

Novartis

AstraZenec

Published 2009

201 Pages

40 Product Profiles from 25+ Companies

Thousands of Metrics
Table of Contents.
Price: $9,995.00 / €6,680.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions